as 01-17-2025 4:00pm EST
Invizyne Technologies Inc is redefining biomanufacturing by leveraging cell-free multi-step enzyme-based systems to efficiently transform natural or renewable resources into highly sought-after chemicals. It believes that its biomanufacturing platform, known as SimplePath, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. its objective with SimplePath is to enable the efficient production of a diverse range of chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform consists of a series of modular cascading enzyme-based biomanufacturing systems that leverage natural processes to perform complex chemical conversions.
Founded: | 2019 | Country: | United States |
Employees: | N/A | City: | MONROVIA |
Market Cap: | 111.5M | IPO Year: | 2024 |
Target Price: | N/A | AVG Volume (30 days): | 52.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.82 | EPS Growth: | N/A |
52 Week Low/High: | $8.50 - $23.00 | Next Earning Date: | 02-15-2025 |
Revenue: | N/A | Revenue Growth: | 145.01% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
IZTC Breaking Stock News: Dive into IZTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "IZTC Invizyne Technologies Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.